Announcement PDF RNS Number : 9445O Fusion Antibodies PLC 12 February 2021 Fusion Antibodies plc ("Fusion" or the "Company") Holding in Company Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been advised that, following a share purchase on 11 February 2021, Paul Warwick holds 814,080 ordinary shares in the Company, representing 3.2 per cent. of the Company's issued share capital. Enquiries: www.fusionantibodies.com Fusion Antibodies plc Dr Paul Kerr, Chief Executive Officer James Fair, Chief Financial Officer Via Walbrook PR Allenby Capital Limited James Reeve / Asha Chotai (Corporate Finance) Tony Quirke (Sales and Corporate Broking) Walbrook PR Anna Dunphy Paul McManus Tel: +44 (0)20 3328 5656 Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com Mob: +44 (0)7876 741 001 Mob: +44 (0)7980 541 893 About Fusion Antibodies plc Fusion is a Belfast based biotechnology company providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue. Fusion is a Collaborative Research Organisation (CRO) which provides antibody discovery, engineering and supply, through to cell line development. At every stage, our client's vision is central to how we work, ensuring the best molecule goes to the clinic. Our world-class humanization and antibody optimization platforms harness the power of the natural diversity of antibodies. To address remaining market needs in antibody discovery, Fusion is creating a fully human antibody library to capture the entire human antibody repertoire. Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster and ultimately speed up the drug development process. The global monoclonal antibody therapeutics market was valued at $95.5 billion in 2017 and is forecast to surpass $174.2 billion in 2026, an increase at a CAGR of 6.9 per cent. for the period 2018 to 2026. In 2018, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $62 billion. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END HOLGPUUUPUPGUBP